The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Silo Pharma Shares Surge on European Patent Office Allowance

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Silo Pharma received a Rule 71(3) communication from the European Patent Office indicating its intent to grant a patent.

2The company holds an exclusive license for the patent application from Columbia University.

Silo Pharma (SILO) shares experienced a significant rally following a positive update regarding its intellectual property portfolio in Europe. The company received a Rule 71(3) communication from the European Patent Office (EPO), indicating an intent to grant a key patent. This patent application is exclusively licensed to Silo Pharma from Columbia University, significantly strengthening the firm's competitive position. Securing patent protection in major international markets is considered a vital milestone for biotechnology companies to safeguard their R&D investments. The move ensures future commercial exclusivity for the underlying technology within the European jurisdiction. Market participants responded bullishly to the news, driving the stock price higher immediately after the announcement.